Tilray Brands, Inc. (TLRY)
USD 0.45
(-0.53%)
USD 0.45
(-0.53%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 892.11 Million USD | -20.34% |
| 2023 | 977.31 Million USD | -3.08% |
| 2022 | 1 Billion USD | -35.37% |
| 2021 | 1.56 Billion USD | 227.82% |
| 2020 | 475.89 Million CAD | -9.11% |
| 2019 | 523.6 Million CAD | 380.55% |
| 2018 | 108.95 Million CAD | 248.65% |
| 2017 | 31.25 Million CAD | 3118.36% |
| 2016 | 971.04 Thousand CAD | 27.4% |
| 2015 | 762.17 Thousand CAD | 7204.72% |
| 2014 | 10.43 Thousand CAD | -5.8% |
| 2013 | 11.07 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 937.2 Million USD | -6.34% |
| 2024 FY | 892.11 Million USD | -8.72% |
| 2024 Q4 | 892.11 Million USD | 2.56% |
| 2024 Q1 | 1 Billion USD | 2.39% |
| 2024 Q3 | 869.81 Million USD | -7.19% |
| 2023 Q3 | 969.12 Million USD | -2.23% |
| 2023 Q1 | 1.02 Billion USD | 2.08% |
| 2023 Q2 | 991.23 Million USD | -3.7% |
| 2023 Q4 | 977.31 Million USD | 0.84% |
| 2023 FY | 977.31 Million USD | -3.08% |
| 2022 Q2 | 1.29 Billion USD | -19.37% |
| 2022 Q4 | 1 Billion USD | -12.96% |
| 2022 FY | 1 Billion USD | -35.37% |
| 2022 Q1 | 1.6 Billion USD | 2.6% |
| 2022 Q3 | 1.15 Billion USD | -10.23% |
| 2021 Q2 | 665.27 Million CAD | 35.91% |
| 2021 Q1 | 489.49 Million CAD | 2.86% |
| 2021 Q3 | 972.32 Million CAD | 46.15% |
| 2021 FY | 1.56 Billion USD | 227.82% |
| 2021 Q4 | 1.56 Billion USD | 60.44% |
| 2020 Q2 | 552.12 Million CAD | 8.8% |
| 2020 Q3 | 550.84 Million CAD | -0.23% |
| 2020 Q4 | 475.89 Million CAD | -13.61% |
| 2020 Q1 | 507.47 Million CAD | -3.08% |
| 2020 FY | 475.89 Million CAD | -9.11% |
| 2019 Q4 | 523.6 Million CAD | 102.34% |
| 2019 FY | 523.6 Million CAD | 380.55% |
| 2019 Q2 | 228.02 Million CAD | 79.19% |
| 2019 Q3 | 258.78 Million CAD | 13.49% |
| 2019 Q1 | 127.25 Million CAD | 16.79% |
| 2018 FY | 108.95 Million CAD | 248.65% |
| 2018 Q3 | 85.1 Million CAD | 112.78% |
| 2018 Q4 | 108.95 Million CAD | 28.03% |
| 2018 Q2 | 39.99 Million CAD | 24.31% |
| 2018 Q1 | 32.17 Million CAD | 2.96% |
| 2017 Q3 | 10.16 Million CAD | 27.47% |
| 2017 Q1 | 7.94 Million CAD | 718.69% |
| 2017 Q2 | 7.97 Million CAD | 0.26% |
| 2017 Q4 | 31.25 Million CAD | 207.59% |
| 2017 FY | 31.25 Million CAD | 3118.36% |
| 2016 Q1 | 1.2 Million CAD | 57.8% |
| 2016 Q2 | 1.2 Million CAD | -0.06% |
| 2016 Q4 | 971.04 Thousand CAD | -18.33% |
| 2016 FY | 971.04 Thousand CAD | 27.4% |
| 2016 Q3 | 1.18 Million CAD | -1.09% |
| 2015 Q3 | 615.99 Thousand CAD | 2214.8% |
| 2015 Q2 | 26.61 Thousand CAD | -3.51% |
| 2015 Q1 | 27.57 Thousand CAD | -72.39% |
| 2015 FY | 762.17 Thousand CAD | 7204.72% |
| 2015 Q4 | 762.17 Thousand CAD | 23.73% |
| 2014 Q4 | 99.9 Thousand CAD | 145.6% |
| 2014 Q3 | 40.67 Thousand CAD | 434.8% |
| 2014 Q2 | 7605.87 CAD | -27.1% |
| 2014 Q1 | 10.43 Thousand CAD | 258.47% |
| 2014 FY | 10.43 Thousand CAD | -5.8% |
| 2013 Q1 | 11.07 Thousand CAD | -40.98% |
| 2013 Q4 | 2910.70 CAD | -80.84% |
| 2013 FY | 11.07 Thousand CAD | 0.0% |
| 2013 Q3 | 15.19 Thousand CAD | -50.64% |
| 2013 Q2 | 30.77 Thousand CAD | 177.87% |
| 2012 Q2 | 48.28 Thousand CAD | 0.0% |
| 2012 Q3 | 6803.25 CAD | -85.91% |
| 2012 Q4 | 18.76 Thousand CAD | 175.84% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Journey Medical Corporation | 56.49 Million USD | -1478.996% |
| Safety Shot Inc | 3.89 Million USD | -22821.555% |
| Bright Green Corporation | 6.43 Million USD | -13756.832% |
| Alvotech | 1.88 Billion USD | 52.612% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -444.289% |
| Cosmos Health Inc. | 30.25 Million USD | -2848.901% |
| Dynavax Technologies Corporation | 375.02 Million USD | -137.883% |
| Embecta Corp. | 2.03 Billion USD | 56.185% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -35.008% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -551.794% |
| Pacira BioSciences, Inc. | 704.25 Million USD | -26.675% |
| PainReform Ltd. | 2.69 Million USD | -33051.877% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -14430.539% |
| SCYNEXIS, Inc. | 55.45 Million USD | -1508.867% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -9600.497% |
| Alpha Teknova, Inc. | 38.55 Million USD | -2214.122% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | -89.139% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 5.883% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -14430.539% |
| Procaps Group, S.A. | 462.06 Million USD | -93.072% |
| Theratechnologies Inc. | 98.63 Million USD | -804.426% |
| Harrow Health, Inc. | 241.75 Million USD | -269.02% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -10088.636% |
| Biofrontera Inc. | 23.13 Million USD | -3755.469% |
| DURECT Corporation | 30.4 Million USD | -2834.016% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -83.013% |
| Cronos Group Inc. | 43.73 Million USD | -1939.773% |
| OptiNose, Inc. | 194.33 Million USD | -359.061% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | -9.145% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1741.505% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -4152.606% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -391.899% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -23550.194% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -1598.746% |
| Radius Health, Inc. | 804.29 Million USD | -10.92% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -6386.081% |
| ProPhase Labs, Inc. | 42.54 Million USD | -1996.928% |
| Phibro Animal Health Corporation | 725.54 Million USD | -22.959% |
| Procaps Group S.A. | 462.06 Million USD | -93.072% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -6262.266% |
| Viatris Inc. | 27.21 Billion USD | 96.722% |
| Rockwell Medical, Inc. | 30.88 Million USD | -2788.793% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -887.084% |
| SIGA Technologies, Inc. | 57.97 Million USD | -1438.735% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -305.877% |
| Shineco, Inc. | 47.6 Million USD | -1774.129% |
| PetIQ, Inc. | 645.22 Million USD | -38.264% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -406309.217% |
| Incannex Healthcare Limited | 5.83 Million USD | -15202.178% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 12.486% |
| Alimera Sciences, Inc. | 107.35 Million USD | -731.005% |
| Silver Spike Investment Corp. | 3 Million USD | -29540.103% |
| Assertio Holdings, Inc. | 148.41 Million USD | -501.092% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -46953.453% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -4085.244% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -12597.367% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -10407.199% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -414.524% |
| Hempacco Co., Inc. | 18.82 Million USD | -4639.655% |
| Talphera, Inc. | 6.29 Million USD | -14083.1% |
| Alvotech | 1.88 Billion USD | 52.612% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -416.87% |
| Lantheus Holdings, Inc. | 835.25 Million USD | -6.807% |
| Currenc Group, Inc. | 177.67 Million USD | -402.104% |
| Kamada Ltd. | 109.96 Million USD | -711.249% |
| Indivior PLC | 1.95 Billion USD | 54.28% |
| Evoke Pharma, Inc. | 9.64 Million USD | -9146.573% |
| Flora Growth Corp. | 17.22 Million USD | -5080.101% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -10407.199% |
| Evolus, Inc. | 209.68 Million USD | -325.452% |
| HUTCHMED (China) Limited | 536.38 Million USD | -66.32% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | -2.132% |
| Akanda Corp. | 12.66 Million USD | -6941.796% |